Pharmaceutical developer Starpharma has secured United Kingdom distribution for its Viraleze antiviral nasal spray.
The Melbourne company has signed a sales and distribution agreement with LloydsPharmacy which operates 1,400 pharmacy stores in the UK and is part of international pharma distributor group McKesson.
McKesson supplies more than 14,000 pharmacies across the UK.
Viraleze spray, which can be stored at room temperature and does not require refrigeration, will be launched online in its first market, the UK next week and will be in store in April.
Viraleze contains SPL7013 (astodrimer sodium), which has been shown in laboratory studies to inactivate respiratory viruses, including more than 99.9 per cent of coronavirus SARS-CoV-2 – the virus that causes COVID-19.
Viraleze is registered for sale in the UK and Europe, with Starpharma now planning a wider European rollout.
Starpharma CEO Dr Jackie Fairley said Viraleze nasal spray would be available as UK consumers emerge from their latest lockdowns.
She said: “Viraleze was developed, manufactured and registered by Starpharma, and we are delighted to see it launched in the UK market.”
Subscribe to our free @AuManufacturing newsletter here.